Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Practical considerations for monitoring patients with chronic myeloid leukemia
Author: Branford, S.
Hughes, T.
Citation: Seminars in Hematology, 2010; 47(4):327-334
Publisher: W B Saunders Co
Issue Date: 2010
ISSN: 0037-1963
Statement of
Susan Branford and Timothy P. Hughes
Abstract: Current routine monitoring strategies for chronic myeloid leukemia (CML) incorporate hematologic, cytogenetic, and molecular analysis. BCR-ABL1 kinase domain mutation analysis is an important assessment in specific circumstances. The recommendations for when and how frequently to undertake these assessments have recently been updated. However, response assessment is not always straightforward and access to some analytical tools may not be available. Pharmacokinetic assessment of imatinib levels may correlate with clinical response and could help in assessing issues of suboptimal response, excessive toxicity, or noncompliance. Here we provide practical considerations for monitoring response, offer suggestions for alternative assessments in case of failure or limited access of analyses, and consider future monitoring tools.
Keywords: Humans
Fusion Proteins, bcr-abl
Antineoplastic Agents
Drug Monitoring
Cytogenetic Analysis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Rights: Crown copyright © 2010 Published by Elsevier Inc.
DOI: 10.1053/j.seminhematol.2010.06.007
Description (link):
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.